Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2022, with the report dated June 28, 2022. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a disclosure of a specific insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $41.9700 |
| Volume | 1,227.261 ADSs |
| Transaction Date | June 22, 2022 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It discloses a single acquisition event within Dr. Barron's GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction is noted as an initial notification for the acquisition of notional ADSs.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The purchase was made within an Executive Supplemental Savings Plan account, not necessarily a direct open-market purchase.
- Market Price Context: The transaction occurred at $41.97 per ADS on June 22, 2022, on the NYSE.
- Scope Limitation: This document does not contain quarterly or annual financial results; investors should refer to Form 20-F or other periodic reports for financial performance data.